Your browser doesn't support javascript.
loading
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Stuart, Robert K; Cripe, Larry D; Maris, Michael B; Cooper, Maureen A; Stone, Richard M; Dakhil, Shaker R; Turturro, Francesco; Stock, Wendy; Mason, James; Shami, Paul J; Strickland, Stephen A; Costa, Luciano J; Borthakur, Gautam; Michelson, Glenn C; Fox, Judith A; Leavitt, Richard D; Ravandi, Farhad.
Affiliation
  • Stuart RK; Medical University of South Carolina, Charleston, SC, USA.
Br J Haematol ; 168(6): 796-805, 2015 Mar.
Article in En | MEDLINE | ID: mdl-25403830
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Thiazoles / Leukemia, Myeloid, Acute / Naphthyridines / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Thiazoles / Leukemia, Myeloid, Acute / Naphthyridines / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article